Research programme: Nav1.7 gain of function mutation diagnostics - Biogen
Latest Information Update: 24 Jun 2015
At a glance
- Originator Convergence Pharmaceuticals
- Developer Biogen; Yale University
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Neuropathic pain
Most Recent Events
- 06 Oct 2014 Clinical trials in Neuropathic pain (Diagnosis) in USA (unspecified route)